After this long run of failed late-stage clinical trials, in April of 2007 AstraZeneca bought vaccine maker MedImmune, paying $15.2 billion primarily for its drug development pipeline. Analysts have criticized this take-over, claiming that AstraZeneca paid too much[8]. ...
Housing around 400 employees, the building brings together staff from AstraZeneca’s Technology Innovation & Delivery Excellence (TIDE) unit, as well as subsidiaries MedImmune, Acerta Pharma, and Pearl Therapeutics into one state-of-the-art facility at the center of the Bay Area’...
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has acquired AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme. LCAT, an enzyme...
ASTRAZENECA MEDIMMUNE (Gaithersburg, MARYLAND, US) Parent Case Data: CROSS-REFERENCE TO RELATED APPLICATIONS This application is a divisional application and claims priority to U.S. application Ser. No. 10/484,569, filed on Jan. 22, 2004 now U.S. Pat. No. 7,125,896 which claims priority...